Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ES-936 is a potent and specific small molecule inhibitor of NAD(P)H:quinone oxidoreductase 1 (NQO1), also known as NAD(P)H dehydrogenase [quinone] 1. It acts as a mechanism-based (irreversible) inhibitor, effectively blocking NQO1 activity at nanomolar concentrations—over a thousand times more potent than the non-specific inhibitor dicoumarol. In cellular systems, ES‑936 rapidly inhibits more than 95% of NQO1 activity within minutes and is stable in media for at least two hours. Its inhibition is highly selective for NQO1 with no significant effects on other cellular reductases or acid-soluble thiols. Preclinical studies show that it induces growth inhibition in certain human cancer cell lines (e.g., pancreatic carcinoma MIA PaCa‑2 and adenocarcinoma BxPC‑3). It has also been used to study the role of NQO1 in drug metabolism and cytotoxicity[2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ES-936.